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ABSTRACT
Objective: To determine the natural human humoral immune responses to the 19 kilodalton
carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP119),
a malaria candidate vaccine antigen and to determine the prevalence of MAD20 and K1
alleles of P. falciparum MSP1.
Design: Community based cross-sectional study.
Setting: Atopi Parish, Apac District, Uganda, 1995.
Subjects: Three hundred and seventy four Ugandans between <1 and 70 years old provided
serum samples.
Main outcome measures: IgG subclass antibodies by ELISA; MAD20 and K1 allelic types of
MSP1 by PCR.
Results: Both the prevalence and the mean concentration of serum IgG1 , and to a lesser
extent IgG3, antibodies increased with age. IgG2 or IgG4 antibodies were virtually non-
existent. The cross-reactivity between the 4 sequence variants (E-KNG, E-TSR, Q-KNG and
Q-TSR) of MSP119 was confirmed; however, a minority of sera preferentially recognised the
KNG but not the TSR variants. All 33 P. falciparum isolates from different parts ofm Uganda
carried the E-TSR (Mad20) allelic type and 3 isolates were mixed infections with E-TSR
(MAD20) and Q-KNG (K1) allelic types, confirming the rarity of the K1 allele in Uganda.
Conclusion: There is a robust IgG1 antibody response to the malaria vaccine candidate
antigen MSP119 which begins at an early age. Future cohort studies are necessary to estblish
the impact of these antibodies on clinical immunity to malaria. The MAD20 allelic type of
MSP1 id predominant in Ugandan P. falciparum isolates.
INTRODUCTION
The merozoite surface protein (MSP1), a 195
kilodalton (kD) protein on the surface of merozoites
which is processed into many shorter polypeptides prior to
the invasion of the erythrocyte, is the subject of intense
investigations aimed at developing Plasmodium falciparum
blood-stage vaccines(1). Evidence from in vitro and
challenge studies in mice and primates suggests that a
vaccine based on MSP1 might have an immunoprophylactic
effect against malaria(2-5). Immunisation with
recombinant Plasmodium yoelii MSP1(6) or a DNA
vaccine encoding Plasmodium yoelii MSP1(7) has
protected mice against P. yoelii sporozoite challenge;
immunised mice exhibited boosting of antibody responses
after infection(8). MSP1 is composed of conserved,
polymorphic and dimorphic sequences. Although the
carboxy terminal 42 kD fragment is dimorphic, with the
two alleles being classified as MAD20-like or K1-like(9),
the 19 kD fragment is essentially conserved with only 4
amino acid differences between the two dimorphic
types(10). This divergence has resulted in the existence of
four possible sequence variants of MSP119 which have
been successfully expressed in the yeast Saccharomyces
cerevisiae as secreted polypeptides(11).
Antibodies to the carboxy terminus of MSP1 are
believed to be responsible for much of the protective effect
of antibodies to native MSP1 . Immunisation of rabbits
with the carboxy terminal 42 kD portion of P. falciparum
MSP1 induced antibodies, which inhibited parasite growth
in vitro(12). Studies of West African children have
demonstrated that the prevalence of antibodies to the C
terminus of MSP1 was associated with resistance to clinical
malaria and high parasitemia in young children(13,14).
However, the correlation between responses to MSP119
and clinical immunity observed in West African children
still remains to be confirmed in other field sites in Africa
which have different malaria transmission patterns. To
this end, we have begun to investigate immunological
responses to MSP119 in Atopi Parish in northern Uganda.
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In this paper, we describe IgG subclass responses to
MSPl19 in Atopi residents. The majority of these subjects
possessed cross-reactive IgG1 antibodies against all four
sequence variants of MSP119. We also observed that
MAD20 was the predominant allelic type of MSPl present
in Ugandan P. falciparum isolates.
MATERlALS AND METHODS
Study population and sample collection: Atopi Parish is
located about 5 km west of Apac Town, 300 km north of
Kampala. The population is predominantly of the Lango tribe
and the major occupation is peasant agriculture. The description
of the study population and preliminary malariometric data has
been reported elsewhere (Egwang et al). During a cross-sectional
survey carried out in December 1995, 1246 subjects were
interviewed using a standard questionnaire and subjected to
medical examination by a clinician. Blood samples from all
subjects were collected in vacutainers containing EDTA. Thin
and thick blood films were made for each sample, stained with
Giemsa, and examined for malaria parasites under high power
microscopy. Serum samples separated from blood were collected
into fresh serum vials and transported on ice to Kampala where
they were stored at -20 °C. Finger prick blood samples from
children were collected onto filter papers (Whatman paper # l);
the filters were air dried, stored individually in plastic envelopes,
and kept at 4°C until genomic DNA was extracted. The
demographic and parasitologic data for 374 subjects whose
serum and parasite isolates were used for the immunological and
parasite genotyping studies are presented in Table 1.
Antigens, immunochemicals and primers: Four variants of
MSP119, the carboxy terminal fragment of Plasmodium
falciparum merozoite surface protein, namely Q-TSR, Q-KNG,
E-TSR, and E-KNG produced in recombinant Saccharomyces
cerevisiae were kindly provided by Dr David Kaslow (Molecular
Vaccine Section, National Institute of Health, Bethesda, MD,
USA). Alkaline phosphatase conjugated murine monoclonal
antibodies to IgGl, IgG2, IgG3, and IgG4 antibodies were
purchased from Zymed Laboratories, Inc, South San Francisco,
CA, USA and from The Binding Site Limited, Birmingham, UK.
Primers and protocols for genotyping P. falciparum isolates at
the MSP1 locus by the polymerase chain reaction (PCR) were
provided by Dr. Lisa Ranford Cartwright (Institute of Cell,
Animal, and Population Biology, University of Edinburgh, UK).
Enzyme-linked immunoadsorbent assays (ELISA): The E-
KNG variant derived from the Palo Alto strain was chosen for
initial studies and IgG subclass antibodies reacting with E-KNG
were detected by ELISA. Immunolon 4 microtitre plates (Dynatech,
UK) were coated overnight at 4°C with 1 µg/ml antigen in
carbonate buffer. Plates were washed three times with phosphate
buffered saline (PBS) containing 0.5 % v/v Tween 20 (PBS/T),
blocked for one hour with 1% powdered skimmed milk in PBS/T
(blocking buffer) and serum samples diluted 1:50 in blocking
buffer were added to the plates in duplicate and incubated for one
hour  at 37°C. The plates were then washed three times in PBS/T
and incubated for one hour at 37°C with alkaline phosphate
conjugated mouse monoclonal antibodies against human IgG1,
IgG2, IgG3, or IgG4 appropriately diluted in PBS/T. After the
final wash, the reactions were developed by adding p-nitrophenyl
phosphate (Sigma) and read at 405 nm after 30 minutes. Serum
samples from 30 Europeans not previously exposed to malaria
were employed as negative controls to obtain the cut-off value for
positive antibody reactions. The cut-off value was calculated as
the mean optical density (OD) plus two standard deviations of the
European sera.
Competition ELISA: We identified two groups of serum
samples: those which reacted strongly with all the variants, and
those which reacted strongly with only E-KNG and Q-KNG
variants when IgGl antibodies were measured. Competition
ELISA was therefore carried out in order to confirm the cross-
reactivity of IgGl antibodies against MSPl19 sequence variants
in the majority of serum samples. Plates were pre-coated with Q-
KNG or E-KNG and blocked as described above. Selected serum
samples in both categories were pre-incubated at room
temperature with increasing quantities of Q-TSR in carbonate
buffer for 5 hours and then added to the wells of the pre-coated
microtitre plates. The plates were washed three times in PBS/T
followed by incubation for one hour at 37°C with 100 µl  of
alkaline phosphate conjugated mouse monoclonal antibodies
against human IgGl. All subsequent steps including development
with the substrate were as described above for ordinary ELISA.
Parasite genotyping for MSP1 Block 17: P. falciparum
DNA was extracted from filter papers, slides, or red blood cell
pellets as described(15-17). We obtained P. falciparum isolates
from other regions of Uganda either as slides (Kabarole) or as red
blood cell pellets (Kampala). PCR primers used for amplifying
Table 1
Demographic and parasitological data for the subjects who provided sera for immunological studies of MSP119
Sex P. falciparum
Age Density
(years) N Male Female Prevalence (%) (GM parasites/µl blood)
     <1 4 3 1 100.0 60.0
    1-5 39 18 21 92.3 1272.7
    6-8 61 35 26 80.3 899.1
  9-10 41 18 23 80.5 300.3
11-14 49 32 17 63.8 296.8
15-20 49 19 30 39.6 314.4
21-30 36 16 20 52.8 125.8
31-40 40 17 23 45.0 151.4
   >40 53 29 24 51.9 137.8
Total 372 187 185 64.1 327.9
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MSPl block 17 included primers l G (5'-AAS/GAT/ATY/TTA/
AAT/TCA/CG- 3') and lH (5'-TT/ATT/TTC/GTT/ACA/AGT/
AGG-3') for the first outer dimorphic PCR. Nested PCR using
the outer PCR product as template was carried out using MAD20-
and K1-specific forward primers designated 1A and 1B,
respectively, as well as a common reverse primer 1C. The
sequences of 1A, 1B, and 1C were 5'-GAG/AAG/TTC/CCA/
TCA/TCA/CCA/C-3', 5'-GAA/TTG/CTG/ATT/TAT/CAA/
CAG-3', and 5'-CAT/CTA/AAT/GTC/TGAIAAC/ATC/C-3',
respectively. Outer PCR was carried out using 1 µl of the P.
falciparum DNA template in a 50-µl reaction volume containing
1.5 mM MgCl2, 200 µM dNTP mix, 1.0 µg/µ1 primers, and
2.5 units of Taq polymerase (Promega) using the following
conditions: pre-PCR incubation at 95°C for 5 min followed by
incubation at 50°C for 5 min, followed by 39 cycles of 95°C for
1 min, 50°C for 45 sec, and 72°C for 1 min; during the last cycle,
the extension at 72°C was for l0 minutes. Nested PCR was
carried out using the inner primers 1A, 1B, and 1C at 1.0 µg /µl
and outer PCR product as template. In this case, pre-PCR
involved incubation of the samples at 94°C for 5 min followed
by incubation at 54°C for 5 min; PCR consisted of 40 cycles, each
cycle in turn consisting of 94°C for 1 min, 54°C for 1 min, and
72°C for 1 min; during the last cycle the extension at 72 °C was
again for 10 minutes. Ten µl of PCR products were run on a 2.5%
agarose gel, stained with ethidium bromide, and photographed
under UV transillumination.
Data analysis: Positive sera were those whose ODs were
greater than the normal range (mean ± 2SD) for control European
sera. Mean OD values were compared using the two sample
Student’s t test for equal variances. Proportions were compared
by obtaining pooled proportions for unpaired samples. Possible
associations between antibody response and age were tested
using the chi-square test for trend analysis.
RESULTS
Increasing prevalence and concentration of antibodies
to MSP119 with age: Three hundred and seventy four
serum samples were tested in ELISA for IgG subclass
reactivity with the E-KNG sequence variant of MSPl19.
The prevalence and the mean concentration of IgG1 and
IgG3 antibodies generally increased with increasing age
(Figure 1, panels a and c; Table 2). Robust IgG1 responses
seen in children 0-1 years old could be attributable to
maternal antibodies; data from these children were excluded
from the analyses. The prevalence of IgG1 antibodies in
children 1-5 years old was lower than in subjects >14 years
old (13.9 versus 61.4 %). This difference was statistically
significant (p < 0.001). Mean OD values for IgG1 increased
with age and, in general, individuals older than 14 years
old had significantly elevated IgG1 levels. IgG3 antibodies,
by contrast, had a delayed evolution, with robust responses
beginning to appear only in children above seven to eight
years old (Figure 1). Mean IgG3 levels remained low
throughout the age groups and were significantly elevated
only in individuals >40 years old (Table 2). Very few sera
contained IgG2 or IgG4 antibodies to MSP119 and this did
not change with age.
Figure 1
IgG subclass responses to MSP119 (E-KNG) as a function of age in a
study population from Atopi Parish, Apac District in Northern Uganda.
Panel (a), IgG1; panel (b), IgG2; panel (c), IgG3; and panel (d), IgG4.
The age groups were defined as 1= 0-1 years, 2 = 1-2 years, 3 = 2-3
years, 4 =3-4 years, 5 =4-5 years, 6 = 5-6 years, 7 =6-7 years, 8 = 7-8
years, 9 = 8-9 years, 10 =10 years, 11=10-12 years, 12 = 12-14 years,
13 =14-16 years, 14 =16-20 years, 15 = 20-30 years, 16 =30-40 years,
17 =>40 years.
Table 2
IgG1 and IgG3 subclass antibodies to MSP119 in sera of Atopi parish residents.
a
Age IgG1 IgG3
(years) N Mean OD (SD) Prevalence (%) N Mean OD (SD) Prevalence (%)
    <1 4 1.107 (1.287) 50.0 5 0.308 (0.239) 40.0
    1-5 36 0.352 (0.625) 13.9 39 0.183 (0.097) 38.5
    6-8 54 0.375 (0.569) 22.2 55 0.230 (0.198) 45.5
  9-10 29 0.439 (0.645) 33.3 36 0.304 (0.428) 55.6
11-14 42 0.612 (0.888) 31.1 41 0.361 (0.538) 53.7
15-20 44 1.024 (0.991)b 61.4b 41 0.344 (0.299) 75.6b
21-30 22 0.380 (0.464) 31.8 25 0.374 (0.284) 68.0b
31-40 22 0.519 (0.711) 31.8 22 0.383 (0.505) 59.1
>40 22 1.511 (1.287)b 63.6b 20 0.719 (0.834)b 85.0b
aValues are means with standard deviations SD in parenthesis and prevalence estimates of serum samples positive for antibodies.
bSignificantly greater (P < 0.05) from the value for children in the age group 1-5 years.
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Antibodies to MSP119 E-KNG cross-react with Q-
TSR: In order to ascertain whether all the serum samples
reacted equally strongly with other MSP119 variants;
thirty six sera from adults with robust IgG1 responses
against E-KNG were tested against all the sequence variants
(E-KNG, E-TSR, Q-KNG and Q-TSR). None of these sera
were able to discriminate between proteins carrying Q or
E, i.e. OD values were closely correlated for Q-TSR
versus E-TSR and values for Q-KNG were closely
correlated with those for E-KNG (Figure 2a, 2b). However,
three sera preferentially bound to KNG rather than TSR
(Figure 2c, 2d). In several experiments, the three sera
reacted with an OD < 0. 5 against TSR variants while
reacting with an OD ~ 2.0 against KNG variants.
Figure 2
OD values for IgG1 reactivity against different MSP119 sequence
variants are correlated. Panel (a), Q-TSR versus E-TSR; panel (b),
Q-KNG versus E-KNG; panel (c), Q-KNG versus Q-TSR; and panel
(d), E-TSR versus E-KNG. Note the discordance between recognition
of Q-KNG and Q-TSR in panel (c) for one serum sample (arrow head)
and between recognition of E-KNG and E-TSR in panel (d) for two
serum samples (arrow heads).
Cross reactivity of IgG1 antibodies to TSR and KNG
was confirmed by competition ELISA (Figure 3). Sera
were pre-incubated with soluble Q-TSR and then added to
plates pre-coated with Q-KNG. Q-TSR inhibited binding
to Q-KNG for two serum samples (795 and 606). These
two sera, representative of the majority of serum samples,
bound equally to Q-KNG and Q-TSR. By contrast, the
binding of two other serum samples (997 and 395) to Q-
KNG was unaffected by pre-incubation with Q-TSR;
these sera reacted with Q-KNG but not to Q-TSR
confirming the lack of cross-reactivity of IgGl anti-Q-
KNG with the Q-TSR variant.
Figure 3
Competition ELISA for IgG1 reactivity against Q-KNG after pre-
incubation with various amounts of Q-TSR. There was competitive
inhibition between Q-KNG and Q-TSR for samples 795 and 606, and
lack of competitive inhibition for samples 997 and 395.
Table 3




Regionb N (E-TSR) (Q-KNG) (MAD20/K1)
Kampala (Central) 17 17 (17/17) 0 (0/17) 2 (2/17)
Kabarole (Western) 8 8 (8/8) 0 (0/8) 0 (0/8)
Apac (Northern) 8 8 (8/8) 0 (0/8) 1 (1/8)
Total 33 33 (33/33) 0 (0/8) 3 (3/33)
Percent 100 0 9
aValues are numbers of samples containing the MSPl allele with the frequency in parenthesis.
bRegions from which the genotyped P. falciparum  isolates were collected.
The predominant allele of MSP119 in Uganda is E-
TSR (MAD 20): The presence of nested PCR products of
approximately 480 and 230 bp representing MAD20 and
Kl alleles, respectively, were scored in 33 individual P.
falciparum isolates from three different regions of  Uganda,
namely, Central (Kampala), Western (Kabarole) and
Northern (Apac) regions (Table 3). All isolates contained
parasites of the E-TSR (MAD20) allelic type. However
three  isolates were mixed infections in which the E-TSR
(MAD20) and Q-KNG (K1) allelic types were also
detected, thus demonstrating the paucity of the K1 allelic
type in these isolates.
DISCUSSION
MSPl19 is a promising P. falciparum blood stage
vaccine currently under development(1). Previous studies
have shown that antibodies to the carboxy terminal fragment
of MSPl are associated with clinical immunity to malaria
in West African children(13,14). The major IgG subclass
response to MSPl19 appears to be the opsonising IgGl and
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IgG3 antibodies which predominate in the sera of clinically
immune individuals and which appear to be responsible
for both inhibition of merozoite invasion of erythrocytes
and killing of intra-erythrocytic parasites by monocytes
(Egan., A.E et al in press). We have undertaken studies of
human IgG subclass responses to P. falciparum MSPl19
in a region of intense malaria transmission in Uganda with
the major goal of studying the role of anti-MSPl19
antibodies in clinical immunity to malaria and to attempt
to extend the findings reported in West African children to
children in this part of Uganda. Our studies have confirmed
that IgGl and IgG3 antibodies are the predominant IgG
antibodies in residents of Atopi Parish and that the mean
levels and prevalence of these antibodies increased with
age. Interestingly, vigorous IgGl responses appeared earlier
and were evident in children as early as five years. Whereas
in the Gambian study there was a distinct paucity of IgG3
antibodies, in the Ugandan study there was a significant
and vigorous response (mean OD values and prevalence)
by IgG3 subclass although strong IgG3 responses were
delayed and appeared only in children above seven to
eight  years. As with the Gambian population, we observed
almost background levels of the IgG2 and IgG4 subclass
responses in Ugandan subjects. Our current data has one
major limitation. The samples were obtained from one
time point in a cross-sectional survey. Thus, although
yielding important insights about the possible roles of
IgG1 and IgG3 antibodies in the host-parasite relationship
during malaria infection in our study population, the
important correlations between antibody levels on the one
hand, and parasite densities or clinical immunity on the
other hand, can not be studied.
We confirmed that the majority of our study population
have cross-reactive antibodies against all MSPl19 variants.
This is in agreement with previous studies in West
Africa(18) and augurs well for the development of a
vaccine based on MSP119. However, we have identified
a small minority (8.3 %) of subjects who recognise only
the KNG but not the TSR variants of MSPl19. The impact
of this finding to the future application of MSPl19 vaccine
remains unclear. Previous work has reported the
predominance of MAD20 allelic types and a paucity of K1
allelic types in African P. falciparum isolates(19, 20). We
have confirmed the abundance of MAD20 and the rarity of
K1 allelic types in P. falciparum isolates from Atopi
Parish and other areas of Uganda.
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